[RXSalesman]

Ipilumimab has been in the US for a little over 2 years. It isn’t cheap. For an average weighted patient, the recommended regimen of 4 doses will cost over $140K.

The real buzz for the Melanoma indiction is the efficacy reported in Clinical trials for the 2 Anti-PD1s.

Of all the new targeted cancer therapies, what brentuximab vedotin is doing for CD30 positive Hodgkin Lymphoma patients I think is the most remarkable.

[Steve_Seattle]

"It isn’t cheap. For an average weighted patient, the recommended regimen of 4 doses will cost over $140K."

Just to double check - $140,000 for four doses? And is that 4 doses per day, per week, per month, or do four doses eliminate the disease?